Celldex Therapeutics reported $66.57M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agenus USD 35.32M 2.51M Dec/2025
Amgen USD 540M 1000K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celldex Therapeutics USD 66.57M 20K Mar/2026
Glaxosmithkline GBP 4.08B 49.43M Dec/2025
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Northwest Biotherapeutics USD 1.52B 1.52B Sep/2025
Pfizer USD 5.7B 13M Mar/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Roche Holding CHF 795.62M 699.54K Dec/2025